Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina
Identifieur interne : 002A60 ( Main/Exploration ); précédent : 002A59; suivant : 002A61Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina
Auteurs : Jean-Claude Tardif [Canada] ; Ian Ford [Royaume-Uni] ; Michal Tendera [Pologne] ; Martial G. Bourassa [Canada] ; Kim Fox [Royaume-Uni]Source :
- European Heart Journal [ 0195-668X ] ; 2005-12.
Descripteurs français
- Wicri :
- topic : Pharmacologie.
English descriptors
- KwdEn :
Abstract
Aims Ivabradine, a new If inhibitor which acts specifically on the pacemaker activity of the sinoatrial node, is a pure heart rate lowering agent. Ivabradine has shown anti-ischaemic and anti-anginal activity in a placebo-controlled trial. The objective of this study was to compare the anti-anginal and anti-ischaemic effects of ivabradine and the beta-blocker atenolol. Methods and results In a double-blinded trial, 939 patients with stable angina were randomized to receive ivabradine 5 mg bid for 4 weeks and then either 7.5 or 10 mg bid for 12 weeks or atenolol 50 mg od for 4 weeks and then 100 mg od for 12 weeks. Patients underwent treadmill exercise tests at randomization (M0) and after 4 (M1) and 16 (M4) weeks of therapy. Increases in total exercise duration (TED) at trough at M4 were 86.8±129.0 and 91.7±118.8 s with ivabradine 7.5 and 10 mg, respectively and 78.8±133.4 s with atenolol 100 mg. Mean differences (SE) when compared with atenolol 100 mg were 10.3 (9.4) and 15.7 (9.5) s in favour of ivabradine 7.5 and 10 mg (P<0.001 for non-inferiority). TED at M1 improved by 64.2±104.0 s with ivabradine 5 mg and by 60.0±114.4 s with atenolol 50 mg (P<0.001 for non-inferiority). Non-inferiority of ivabradine was shown at all doses and for all criteria. The number of angina attacks was decreased by two-thirds with both ivabradine and atenolol. Conclusion Ivabradine is as effective as atenolol in patients with stable angina.
Url:
DOI: 10.1093/eurheartj/ehi586
Affiliations:
- Canada, Pologne, Royaume-Uni
- Angleterre, Grand Londres, Écosse
- Glasgow, Londres
- Université de Glasgow
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002252
- to stream Istex, to step Curation: 002252
- to stream Istex, to step Checkpoint: 000C88
- to stream Main, to step Merge: 002D92
- to stream Main, to step Curation: 002A60
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina</title><author><name sortKey="Tardif, Jean Claude" sort="Tardif, Jean Claude" uniqKey="Tardif J" first="Jean-Claude" last="Tardif">Jean-Claude Tardif</name></author><author><name sortKey="Ford, Ian" sort="Ford, Ian" uniqKey="Ford I" first="Ian" last="Ford">Ian Ford</name></author><author><name sortKey="Tendera, Michal" sort="Tendera, Michal" uniqKey="Tendera M" first="Michal" last="Tendera">Michal Tendera</name></author><author><name sortKey="Bourassa, Martial G" sort="Bourassa, Martial G" uniqKey="Bourassa M" first="Martial G." last="Bourassa">Martial G. Bourassa</name></author><author><name sortKey="Fox, Kim" sort="Fox, Kim" uniqKey="Fox K" first="Kim" last="Fox">Kim Fox</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FFDB40B6378C527F9C348E37BB2115FB0999E565</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1093/eurheartj/ehi586</idno><idno type="url">https://api-v5.istex.fr/document/FFDB40B6378C527F9C348E37BB2115FB0999E565/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002252</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002252</idno><idno type="wicri:Area/Istex/Curation">002252</idno><idno type="wicri:Area/Istex/Checkpoint">000C88</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000C88</idno><idno type="wicri:doubleKey">0195-668X:2005:Tardif J:efficacy:of:ivabradine</idno><idno type="wicri:Area/Main/Merge">002D92</idno><idno type="wicri:Area/Main/Curation">002A60</idno><idno type="wicri:Area/Main/Exploration">002A60</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina</title><author><name sortKey="Tardif, Jean Claude" sort="Tardif, Jean Claude" uniqKey="Tardif J" first="Jean-Claude" last="Tardif">Jean-Claude Tardif</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8</wicri:regionArea><wicri:noRegion>Quebec H1T 1C8</wicri:noRegion></affiliation><affiliation><wicri:noCountry code="syntax">???</wicri:noCountry></affiliation><affiliation></affiliation></author><author><name sortKey="Ford, Ian" sort="Ford, Ian" uniqKey="Ford I" first="Ian" last="Ford">Ian Ford</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Glasgow, Scotland</wicri:regionArea><orgName type="university">Université de Glasgow</orgName><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName></affiliation></author><author><name sortKey="Tendera, Michal" sort="Tendera, Michal" uniqKey="Tendera M" first="Michal" last="Tendera">Michal Tendera</name><affiliation wicri:level="1"><country xml:lang="fr">Pologne</country><wicri:regionArea>Slaska Akademia Medyczna, Katowice</wicri:regionArea><wicri:noRegion>Katowice</wicri:noRegion></affiliation></author><author><name sortKey="Bourassa, Martial G" sort="Bourassa, Martial G" uniqKey="Bourassa M" first="Martial G." last="Bourassa">Martial G. Bourassa</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8</wicri:regionArea><wicri:noRegion>Quebec H1T 1C8</wicri:noRegion></affiliation></author><author><name sortKey="Fox, Kim" sort="Fox, Kim" uniqKey="Fox K" first="Kim" last="Fox">Kim Fox</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Royal Brompton Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">European Heart Journal</title><title level="j" type="abbrev">Eur Heart J</title><idno type="ISSN">0195-668X</idno><idno type="eISSN">1522-9645</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2005-12">2005-12</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">23</biblScope><biblScope unit="page" from="2529">2529</biblScope><biblScope unit="page" to="2536">2536</biblScope></imprint><idno type="ISSN">0195-668X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0195-668X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angina</term><term>Heart rate</term><term>Pharmacology</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Pharmacologie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Aims Ivabradine, a new If inhibitor which acts specifically on the pacemaker activity of the sinoatrial node, is a pure heart rate lowering agent. Ivabradine has shown anti-ischaemic and anti-anginal activity in a placebo-controlled trial. The objective of this study was to compare the anti-anginal and anti-ischaemic effects of ivabradine and the beta-blocker atenolol. Methods and results In a double-blinded trial, 939 patients with stable angina were randomized to receive ivabradine 5 mg bid for 4 weeks and then either 7.5 or 10 mg bid for 12 weeks or atenolol 50 mg od for 4 weeks and then 100 mg od for 12 weeks. Patients underwent treadmill exercise tests at randomization (M0) and after 4 (M1) and 16 (M4) weeks of therapy. Increases in total exercise duration (TED) at trough at M4 were 86.8±129.0 and 91.7±118.8 s with ivabradine 7.5 and 10 mg, respectively and 78.8±133.4 s with atenolol 100 mg. Mean differences (SE) when compared with atenolol 100 mg were 10.3 (9.4) and 15.7 (9.5) s in favour of ivabradine 7.5 and 10 mg (P<0.001 for non-inferiority). TED at M1 improved by 64.2±104.0 s with ivabradine 5 mg and by 60.0±114.4 s with atenolol 50 mg (P<0.001 for non-inferiority). Non-inferiority of ivabradine was shown at all doses and for all criteria. The number of angina attacks was decreased by two-thirds with both ivabradine and atenolol. Conclusion Ivabradine is as effective as atenolol in patients with stable angina.</div></front></TEI><affiliations><list><country><li>Canada</li><li>Pologne</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li><li>Écosse</li></region><settlement><li>Glasgow</li><li>Londres</li></settlement><orgName><li>Université de Glasgow</li></orgName></list><tree><country name="Canada"><noRegion><name sortKey="Tardif, Jean Claude" sort="Tardif, Jean Claude" uniqKey="Tardif J" first="Jean-Claude" last="Tardif">Jean-Claude Tardif</name></noRegion><name sortKey="Bourassa, Martial G" sort="Bourassa, Martial G" uniqKey="Bourassa M" first="Martial G." last="Bourassa">Martial G. Bourassa</name></country><country name="Royaume-Uni"><region name="Écosse"><name sortKey="Ford, Ian" sort="Ford, Ian" uniqKey="Ford I" first="Ian" last="Ford">Ian Ford</name></region><name sortKey="Fox, Kim" sort="Fox, Kim" uniqKey="Fox K" first="Kim" last="Fox">Kim Fox</name></country><country name="Pologne"><noRegion><name sortKey="Tendera, Michal" sort="Tendera, Michal" uniqKey="Tendera M" first="Michal" last="Tendera">Michal Tendera</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A60 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002A60 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:FFDB40B6378C527F9C348E37BB2115FB0999E565
|texte= Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina
}}
| This area was generated with Dilib version V0.6.29. |  |